New views on the treatment of uterine leiomyoma in women of reproductive age

А. Г. Корнацька, О. О. Ревенько, І. С. Колесніченко, М. А. Флаксемберг, Г. Ю. Обухова

Abstract


Uterine leiomyoma is the most common reproductive system disease in women of fertile age, which takes the leading place in frequency among tumors of the female sexual sphere. It is diagnosed in 20–70% of women of reproductive age. The uterine leiomyoma is still often treated surgically, and is the most common cause of hysterectomies.

The article examines the issues of increasing the effectiveness of treatment of uterine leiomyoma and its complications in women of reproductive age by using combined methods of conservative treatment. The results of examination and treatment of 55 patients aged 27–45 with different forms of leiomyoma are presented: intramural nodes (18–32.7%), intramuralsubserous (21–38.3%) and intramural-submucous (16–29.0%). The size of the dominant node varied from 4.5 to 12 cm. Clinical manifestations of leiomyoma was hyperpolimenorrhea (82.3%), lower abdominal pain (34.7%), frequent urination (15%). Also, 86% of women suffered from a decrease in hemoglobin in the blood.

In respect of all patients, organ-preserving surgical treatment was planned in connection with the desire of women to giving birth to a child. Patients took ulipristal acetate in a continuous regimen of 5 mg per day and indole-3-carbinol with epigallocatechin-3-gallate 1 tablet 2 times a day for 12 weeks. Women with anemia concurrently with this basic therapy took iron preparations inside.

43 (78.3%) women had amenorrhea since the beginning of treatment within a month. The mean decrease in the size of the uterus was 40.7%. After the end of treatment, 49 (89.0%) patients successfully underwent conservative myomectomy, and in 6 (11.0%) patients after the termination of treatment surgical intervention was avoided. During the year after the termination of the course of treatment 13 women became pregnant.

In using the combination therapy with ulipristal acetate in combination with indole-3-carbinol and epigallocatechin-3-gallate for 3 months the hemoglobin level was normalized, and the size of the leiomyoma was decreased, which is important for the safe operation. This therapy is a method of choice for the treatment of young women, who intend to exercise their reproductive function.


Keywords


uterine leiomyoma; infertility; combined therapy

References


Vdovichenko, Y.P., Ledin, D.S. “Infertility in women with uterine leiomyoma.” Pediatrics, obstetrics and gynecology 6 (2005): 89–93.

Veropotvelyan, P.M., Veropotvelyan, M.P., Horuk, P.S., Kucher, N.M. “Uterine myoma – modern views on etiopathogenesis and methods of treatment.” Pediatrics, obstetrics and gynecology 2 (2010): 83–91.

Ivaniuta, S.O., Ivaniuta, L.I. “Discussion issues of endosurgery in women of reproductive age.” Woman health 6 (2010): 55–7.

Osinovskaya, N.S., Ivashchenko, Т.Е., Dzhemlikhanova, L.H., et al. “Peculiarities of estrogen and progesterone receptors polymorphism in women with uterine myoma.” Journal of Obstetrics and Women’s Diseases Vol. 51 Issue 3 (2012): 109–14.

Savelyeva, T.M., Kurtsev, M.A., Brausenko, V.G., et al. “Endoscopic myomectomy: for and against.” Questions of gynecology, obstetrics and perinatology 6.1 (2007): 57–60.

Description of the drug Epigalin®.

Fernandez, H. “Update of myoma management – introduction.” J Gynecol Obstet Biol Reprod (Paris) 40.8 (2011): 856.

Mara, M., Fucikova, Z., Maskova, J., et al. “Uterine fibroid embolization versus myomectomy in women wishing to preserve fertility: preliminary results of a randomized controlled trial.” Eur J Obstet Gynecol Reprod Biol 126.2 (2006): 226–33.


GOST Style Citations


1. Вдовиченко, Ю. П. Неплідність у жінок із лейоміомою матки / Ю.П. Вдовиченко, Д.С. Ледін // Педіатрія, акушерство та гінекологія. – 2005. – № 6. – C. 89–93.

2. Веропотвелян, П.М. Міома матки – сучасні погляди на етіопатогенез та методи лікування / П.М. Веропотвелян, М.П. Веропотвелян, П.С. Горук, Н. М. Кучер // Педіатрія, акушерство та гінекологія. – 2010. – №2. – С. 83–91.

3. Іванюта, С.О. Дискусійні питання ендохірургії в жінок репродуктивного віку / С.О. Іванюта, Л.І. Іванюта // Здоровье женщины. – 2010. – № 6. – С. 55–57.

4. Осиновская, Н.С. Особенности полиморфизма рецепторов эстрогена и прогестерона у женщин с миомой матки / Н.С. Осиновская, Т.Э. Иващенко, Л.Х. Джемлиханова и др. // Журнал акушерства и женских болезней. – 2012. – Т. 51, Вып. 3. – С. 109–114.

5. Савельева, Т.М. Эндоскопическая миомэктомия: за и против / Т.М. Савельева, М.А. Курцев, В.Г. Браусенко и др. // Вопросы гинекологии, акушерства и перинатологии. – 2007. – №6 (1). – С. 57–60.

6. Інструкція до препарату Епігалін®.

Description of the drug Epigalin®.

7. Fernandez, H. “Update of myoma management – introduction.” J Gynecol Obstet Biol Reprod (Paris) 40.8 (2011): 856.

8. Mara, M., Fucikova, Z., Maskova, J., et al. “Uterine fibroid embolization versus myomectomy in women wishing to preserve fertility: preliminary results of a randomized controlled trial.” Eur J Obstet Gynecol Reprod Biol 126.2 (2006): 226–33.





DOI: https://doi.org/10.18370/2309-4117.2017.36.82-85

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)